An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 02 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 02 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 12 Dec 2017 According to the results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology, the study had an observation arm which was discontinued out of consideration for trial beneficence, and the trial continued accrual as a single arm study of romiplostim